Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Q3 2026 earnings

Reported October 12, 2026 · After market close

Revenue$673.1MBeat by $648.7M
EPS$4.73Beat by $5.33
Revenue estimate$24.3M
EPS estimate-$0.60
“At the same time, Sanofi advanced our oral STAT6 degrader into the clinic, and we advanced our CBL-B inhibitor NX-1607 into Phase 1b expansion cohorts across four solid tumor indications.”
Arthur T. Sands

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$673.1M+8,426%
Operating income$559.5M+712%
Net income$549.8M+736%
EPS (diluted)$4.73+559%

Balance sheet

See full
Cash & equivalents$721.0M+808%
Total debt$65.3M+15.7%
Total equity$968.3M+160%
Total assets$1.2B+129%

Cash flow

See full
Operating cash flow$615.6M+1,173%
CapEx$1.4M-48.7%
Free cash flow$614.2M+1,122%

Valuation & ratios

Valuation

as of 10/12/26
See full
Market cap$2.32B+210%
Enterprise value$1.66B+130%
P/E7.9×—
P/S3.3×-5.6×

Profitability

See full
Operating margin41.3%+21.9pp
Net margin42%+22.4pp
FCF margin52.7%+28.5pp

Returns & leverage

See full
Return on equity44%+27.5pp
Debt / equity0.1×-0.1×
Current ratio8.4×+3.1×

FAQ

When did Nurix Therapeutics, Inc. report Q3 2026 earnings?
Nurix Therapeutics, Inc. (NRIX) reported Q3 2026 earnings on October 12, 2026 after market close.
What were Nurix Therapeutics, Inc.'s Q3 2026 revenue and EPS?
Nurix Therapeutics, Inc. reported revenue of $673.1M and eps of $4.73 for Q3 2026.
Did Nurix Therapeutics, Inc. beat estimates in Q3 2026?
Revenue beat the consensus estimate of $24.3M by $648.7M. EPS beat the consensus estimate of $-0.60 by $5.33.
How did Nurix Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8426.3% from $7.9M a year earlier.
Where can I find Nurix Therapeutics, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001549595-26-000048) and the 10-Q periodic report (0001549595-26-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.